LyoGenesis

LyoGenesis is a clinical-stage biotechnology company developing a novel platform for organ regeneration. The company's technology uses the lymph node as a bioreactor to grow functioning ectopic organs, such as the liver, kidney, and thymus. Their lead program, LYO-H001, involves the endoscopic ultrasound-guided injection of allogeneic hepatocytes into a patient's lymph node to treat end-stage liver disease. This approach aims to provide a scalable alternative to full organ transplantation by leveraging the body's own vascularization and growth factors within the lymphatic system. LyoGenesis is also expanding its pipeline to address metabolic diseases like Type 1 diabetes and age-related immune decline.